Ars Pharmaceuticals Inc (SPRY) Stock Price, Quote & News

Latest News on SPRY

Mar 20, 2025, 3:31 PM EDT - 13 days ago

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

Mar 20, 2025, 1:28 PM EDT - 13 days ago

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 13 days ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 4:10 PM EST - 4 weeks ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 3, 2025, 4:35 PM EST - 4 weeks ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Feb 20, 2025, 7:02 PM EST - 5 weeks ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 18, 2025, 8:00 AM EST - 6 weeks ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 6, 2025, 1:04 AM EST - 2 months ago

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Jan 6, 2025, 8:00 AM EST - 3 months ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Dec 19, 2024, 5:25 PM EST - 3 months ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 12, 2024, 2:32 PM EST - 3 months ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Dec 4, 2024, 8:00 AM EST - 4 months ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Nov 13, 2024, 12:40 PM EST - 5 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:30 AM EST - 5 months ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 11, 2024, 7:41 AM EST - 5 months ago

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

Nov 11, 2024, 7:00 AM EST - 5 months ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Nov 9, 2024, 5:30 PM EST - 5 months ago

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Nov 4, 2024, 11:00 AM EST - 5 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 5 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 30, 2024, 11:00 AM EDT - 5 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 24, 2024, 8:30 AM EDT - 5 months ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 23, 2024, 11:00 AM EDT - 5 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Oct 19, 2024, 11:00 AM EDT - 5 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 17, 2024, 11:00 AM EDT - 5 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

$The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions$

Oct 8, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions

Oct 5, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

Oct 3, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Assist The Schall Law Firm

Oct 1, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Sep 29, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Contact The Schall Law Firm

Sep 28, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 27, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors Are Invited To Assist The Schall Law Firm

Sep 24, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 23, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Should Contact The Schall Law Firm

Sep 20, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Urges Stockholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 19, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And Investors With Losses Should Contact The Schall Law Firm

Sep 17, 2024, 11:00 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And The Schall Law Firm Wants Investors To Help With An Inquiry

$The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc For Securities Related Infractions And Shareholders Are Invited To Lend A Hand$

Sep 16, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc For Securities Related Infractions And Shareholders Are Invited To Lend A Hand

Sep 15, 2024, 11:00 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Investors To Join An Inquiry

Sep 14, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc's Possible Securities Fraud And Stockholders Are Invited To Play A Part

Sep 12, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Has Launched An Inquiry In ARS Pharmaceuticals Inc's Possible Securities Fraud And Stakeholders Are Urged To Reach Out

Sep 10, 2024, 4:05 PM EDT - 7 months ago

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 11:00 AM EDT - 7 months ago

Market Cap	1.23B
Revenue (ttm)	89.15M
Net Income (ttm)	8.00M
EPS (ttm)	N/A
PE Ratio	157.25
Forward PE	N/A
Profit Margin	8.97%
Debt to Equity Ratio	0.27

Volume	1,534,100
Avg Vol	1,592,494
Day's Range	N/A - N/A
Shares Out	98.12M
Stochastic %K	21%
Beta	1.04
Analysts	Strong Sell
Price Target	$31.60